Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Tanveer Sobhan

Psychiatry Tamarac, FL Medical Doctor

NPI 1780726836 CMS profile 171993

7481 W Oakland Park Blvd Ste 100, Ste 100, Tamarac, FL 33319

Open in the dashboard

General payments

$758

40 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Tanveer Sobhan of Tamarac, FL is reported in the CMS Open Payments database as having received $758 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $146 7
2019 General $613 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tanveer Sobhan
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Tanveer Sobhan were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Tanveer Sobhan Psychiatry median Middle half National median
2019 $613 $184 $59–$605 $163
2020 $146 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Neurocrine Biosciences, Inc. $214 15 payments
  2. Otsuka America Pharmaceutical, Inc. $178 10 payments
  3. Teva Pharmaceuticals USA, Inc. $111 1 payment
  4. Vanda Pharmaceuticals Inc. $91 5 payments
  5. Allergan Inc. $24 1 payment
  6. LivaNova USA, Inc. $23 1 payment
  7. Lundbeck LLC $21 1 payment
  8. Sunovion Pharmaceuticals Inc. $19 1 payment
  9. Ironshore Pharmaceuticals Inc. $18 1 payment
  10. Bausch Health US, LLC $16 1 payment
  11. Other $44 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $648 39 payments
  2. Education $111 1 payment
Products named General payments · program years 2019–2020
  1. INGREZZA $214 15 payments
  2. FANAPT $91 5 payments
  3. HETLIOZ $91 5 payments
  4. ABILIFY MAINTENA $83 4 payments
  5. REXULTI Psychiatry $71 5 payments
  6. VRAYLAR $24 1 payment
  7. ABILIFY MYCITE $23 1 payment
  8. VNS Therapy $23 1 payment
  9. REXULTI Psychiatry $21 1 payment
  10. LATUDA $19 1 payment
  11. Other $78 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 82 drugs

Part D claims

15,886

Median for Psychiatry: 574

Drug cost

$778,255

Median for Psychiatry: $27,624

Branded share of claims

13.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 15 $120,707
Austedo Deutetrabenazine Brand 19 $115,854
Invega Sustenna Paliperidone Palmitate Brand 51 $115,023
Abilify Maintena Aripiprazole Brand 15 $39,430
Vraylar Cariprazine Hcl Brand 27 $38,294
Aripiprazole Generic 426 $30,924
Fanapt Iloperidone Brand 11 $26,306
Rexulti Brexpiprazole Brand 15 $23,488
Lurasidone Hcl Generic 115 $21,997
Risperdal Consta Risperidone Microspheres Brand 17 $16,612

The 10 drugs with the highest cost, of 82 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$107,743

Medicare's payments for the services billed

Medicare patients

142

Average age 59

Services billed

1,195

89 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 67%
High blood pressure 52%
Arthritis 37%
Diabetes 27%
Chronic kidney disease 20%
COPD 15%
Ischemic heart disease 13%
Cancer 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record